Mong Cho
YOU?
Author Swipe
View article: Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials
Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials Open
Over the past decade, oncolytic viruses (OVs) have been developed as a promising treatment alone or in combination in immuno-oncology but have faced challenges in late-stage clinical trials. Our retrospective reanalysis of vaccinia oncolyt…
View article: Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Methods PDF file - 44K, GLP toxicology study, In vivo imaging and mouse immunohistochemical analyses
View article: Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specific…
View article: Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 2 PDF file - 144K, Bevacizumab reduces TK1 levels & blocks VEGF-mediated JX-594 sensitization in HUVECs, demonstrated by decreased transgene expression (GFP) and decreased burst size
View article: Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 1 PDF file - 74K, VEGF- and FGF-2 stimulate vaccinia replication
View article: Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Table 1 PDF file - 30K, Rabbit GLP toxicology study of intravenous JX-594
View article: Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Video 1 MPG file - 708K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4a (baseline; prior to JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic
View article: Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Video 2 MPG file - 1158K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4b (baseline; 5 days post JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic
View article: Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 4 PDF file - 69K, Day 5 enhancement waterfall plot
View article: Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 3 PDF file - 83K, Normal fibroblasts (GM38 cells) do not express VEGFR2 and are not sensitized to JX-594 infection upon incubation with VEGF
View article: Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Video 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Video 1 MPG file - 708K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4a (baseline; prior to JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic
View article: Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Video 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Video 2 MPG file - 1158K, 3-dimensional tumor model of 10 cm HCC tumor depicted in Fig. 4b (baseline; 5 days post JX-594 treatment). Beige = perfused; green = hypoperfused; red = necrotic
View article: Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Methods PDF file - 44K, GLP toxicology study, In vivo imaging and mouse immunohistochemical analyses
View article: Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 4 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 4 PDF file - 69K, Day 5 enhancement waterfall plot
View article: Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 2 PDF file - 144K, Bevacizumab reduces TK1 levels & blocks VEGF-mediated JX-594 sensitization in HUVECs, demonstrated by decreased transgene expression (GFP) and decreased burst size
View article: Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specific…
View article: Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Table 1 PDF file - 30K, Rabbit GLP toxicology study of intravenous JX-594
View article: Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 1 PDF file - 74K, VEGF- and FGF-2 stimulate vaccinia replication
View article: Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans Open
Supplementary Figure 3 PDF file - 83K, Normal fibroblasts (GM38 cells) do not express VEGFR2 and are not sensitized to JX-594 infection upon incubation with VEGF
View article: Primary Biliary Cholangitis with Ankylosing Spondylitis
Primary Biliary Cholangitis with Ankylosing Spondylitis Open
Primary biliary cholangitis is a chronic inflammatory autoimmune liver disease that is characterized by a positive antimitochondrial antibodies test and progressive destruction of the small intrahepatic bile duct. Ankylosing spondylitis is…
View article: Plug-assisted retrograde transvenous obliteration via gastrocaval shunt for the gastric variceal bleeding
Plug-assisted retrograde transvenous obliteration via gastrocaval shunt for the gastric variceal bleeding Open
Rationale: Most gastric varices at the fundus drain into the left renal vein via the gastrorenal shunt (80–85% of cases) or the inferior vena cava via the gastrocaval shunt (10–15%). Therefore, plug-assisted retrograde transvenous oblitera…
View article: Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials Open
G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that observed in a pooled analysis of a global pan-genotypic population o…
View article: Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma Open
High AFP levels and AFP non-responders were independently associated with poor outcomes after TACE. AFP holds clinical implications for detailed risk stratification upon achieving a CR after TACE.
View article: Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma Open
Background: Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although several data regarding the efficacy of sequential therapy with sorafenib an…
View article: Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase
Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase Open
Viral replication of thymidine kinase deleted (tk−) vaccinia virus (VV) is attenuated in resting normal cells, enabling cancer selectivity, however, replication potency of VV-tk− appears to be diminished in cancer cells. Previously, we fou…
View article: Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution Open
These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities.